The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN6490 in healthy adult participants The secondary objectives of the study are to: * Characterize the pharmacokinetic (PK) profile of single IV and SC doses of REGN6490 in healthy adult participants * Assess immunogenicity of REGN6490 in healthy adult participants dosed with a single IV or SC dose of REGN6490
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
57
Regeneron Study Site
Ghent, Belgium
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
TEAEs include abnormal laboratory testing, vital signs and electrocardiograms (ECGs)
Time frame: Up to Week 16
Serum Concentration of REGN6490 over time
Time frame: Up to Week 16
Incidence of Treatment-Emergent REGN6490 Anti-Drug Antibodies (ADAs)
Time frame: Up to Week 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.